July 28th 2021
It is difficult to dispute that these are troubling times for government officials and public health agencies.
March 24th 2021
Costs associated with anticancer therapeutics continue to rise, although it also is recognized that the overall effectiveness of therapy has improved.
February 24th 2021
Maurie Markman, MD, discusses how privacy and consent in clinical cancer trials have improved over the years.
December 1st 2020
The repercussions of delays in diagnosing cancer, either through screening or the presence of early symptoms, and of required modifications in standard-of-care management paradigms in the COVID-19 era are only now beginning to be fully appreciated.
November 16th 2020
The management of carcinoma of the cervix represents a remarkable dichotomy.
August 29th 2020
When is it appropriate to accept a specific strategy, either formally or informally, as a standard-of-care option in managing the treatment of patients with cancer in a particular clinical setting?